Glaukos
GKOS
#2702
Rank
$6.13 B
Marketcap
$106.87
Share price
-1.47%
Change (1 day)
-22.94%
Change (1 year)

P/E ratio for Glaukos (GKOS)

P/E ratio as of December 2025 (TTM): -69.4

According to Glaukos's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -69.3961. At the end of 2024 the company had a P/E ratio of -52.2.

P/E ratio history for Glaukos from 2015 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-52.282.71%
2023-28.636.81%
2022-20.9-49.21%
2021-41.149.26%
2020-27.6-117.21%
2019160-205.53%
2018-152-100%
2017< -1000-1.4439625997465E+18%
2016256-11632.49%
2015-2.22

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
ICU Medical
ICUI
-460 562.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Integra LifeSciences
IART
-2.07-97.01%๐Ÿ‡บ๐Ÿ‡ธ USA
AtriCure
ATRC
-65.1-6.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Hill-Rom
HRC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.